journal
https://read.qxmd.com/read/37732944/the-feasibility-of-implementing-toronto-childhood-cancer-stage-guidelines-and-estimating-the-impact-on-outcome-for-childhood-cancers-in-seven-pediatric-oncology-units-in-sub-saharan-africa-a-study-from-the-franco-african-pediatric-oncology-group
#1
JOURNAL ARTICLE
Brenda Mallon, Rolande Kaboré, Line Couitchere, Fatou Binetou Akonde, Mbolanirina Lala Rakotomahefa Narison, Aléine Budiongo, Tankélé Arsène Dackono, Angel Pondy, Francis Diedhiou, Catherine Patte, Eva Steliarova-Foucher, Jacqueline Clavel
BACKGROUND: The improvement of childhood cancer outcome is determined by early diagnosis, effective treatment, supportive care, and adequate medical follow-up. Stage at diagnosis may reflect timeliness of diagnosis, therefore standardized registration of stage is essential for interpretation of regional differences and time trends in survival. Here, we describe the feasibility of implementing the Toronto Childhood Cancer Stage Guidelines (hereafter Toronto Guidelines [TG]) in the hospital-based cancer registry of the Franco-African Pediatric Oncology Group (GFAOP), and assess the impact of TG stage on outcome in pediatric oncology units (POUs) in seven low- and middle-income countries in sub-Saharan Africa (SSA)...
September 21, 2023: Pediatric Blood & Cancer
https://read.qxmd.com/read/37731177/sports-participation-in-chronic-immune-thrombocytopenia-safer-than-you-thought
#2
JOURNAL ARTICLE
Char M Witmer, Michele P Lambert
BACKGROUND/OBJECTIVES: Pediatric patients with chronic immune thrombocytopenia (ITP) commonly have activity limitations placed to prevent injury without data guiding clinical decision-making. The objective of this study was to determine risk factors associated with injury in children with chronic ITP. DESIGN/METHODS: Retrospective single-center cohort study from January 1, 2008 to March 31, 2019 in subjects age 5-21 years with chronic ITP (platelet count < 100,000/µL for >1 year)...
September 20, 2023: Pediatric Blood & Cancer
https://read.qxmd.com/read/37731174/cyclin-d2-gene-variance-and-expression-level-in-pediatric-acute-lymphoblastic-leukemia
#3
JOURNAL ARTICLE
Reham Abdel Haleem Abo Elwafa, Magdy El Bordiny, Mostafa Salama, Amira Fawzy, Omneya Magdy Omar
BACKGROUND: Cyclin D2 (CCND2) is a crucial player in cell cycle regulation. CCND2 polymorphisms contribute to cancer predisposition. OBJECTIVES: To evaluate the association of CCND2 rs3217927 single nucleotide polymorphisms (SNP) and its expression levels with acute lymphoblastic leukemia (ALL) susceptibility in Egyptian children and its potential prognostic role. METHODS: The 5' nuclease allelic discrimination assay was used to evaluate the frequency of CCND2 rs3217927 SNP in 80 newly diagnosed children with ALL and 80 age- and sex-matched controls...
September 20, 2023: Pediatric Blood & Cancer
https://read.qxmd.com/read/37728944/parathyroid-adenoma-with-a-somatic-casr-pathogenic-variant-a-pediatric-case-report
#4
LETTER
Kento Kawata, Takeshi Sato, Misa Honda, Satoshi Narumi, Kaori Kameyama, Tomohiro Ishii, Tomonobu Hasegawa
No abstract text is available yet for this article.
September 20, 2023: Pediatric Blood & Cancer
https://read.qxmd.com/read/37728943/the-value-of-reporting-on-end-of-treatment-outcome-of-patients-in-low-income-settings
#5
JOURNAL ARTICLE
Trijn Israels, Ramandeep Singh Arora, Lillian Sung
No abstract text is available yet for this article.
September 20, 2023: Pediatric Blood & Cancer
https://read.qxmd.com/read/37728014/parental-experiences-of-the-informed-consent-process-in-randomized-clinical-trials-a-nordic-study
#6
JOURNAL ARTICLE
Nina Mogensen, Ulrika Kreicbergs, Birgitte Klug Albertsen, Päivi Lähteenmäki, Mats Heyman, Arja Harila
BACKGROUND: Randomized clinical trials (RCTs) are an essential part of improving acute lymphoblastic leukemia (ALL) treatment. This population-based questionnaire study investigated parents' experiences of the informed consent process in the RCTs within the Nordic NOPHO (Nordic Society of Paediatric Haematology and Oncology) ALL2008 trial. PROCEDURE: Parents in Sweden, Denmark, and Finland whose child was alive and in first remission after end of therapy and who were asked to participate in any RCT in the ALL2008 protocol, were asked to complete 15 questions/items regarding their experience of the RCT consent process...
September 20, 2023: Pediatric Blood & Cancer
https://read.qxmd.com/read/37726889/feasibility-and-preliminary-efficacy-of-the-balance-program-to-reduce-pain-related-disability-in-pediatric-sickle-cell-disease
#7
JOURNAL ARTICLE
Megan E Connolly, Sydney Forman, Christina M Sharkey, Stephanie Merwin, Deepika S Darbari, Steven J Hardy
BACKGROUND: Sickle cell disease (SCD) pain is associated with functional impairment, and treatment is often limited to pharmacological approaches with unwanted side effects. Although behavioral interventions exist for non-SCD pain populations, interventions designed to address pain-related impairment in SCD are lacking. METHODS: Twenty youth (9-17 years) with SCD completed a four-week telemedicine pain intervention (NCT04388241). Participants and caregivers completed baseline and post-intervention PROMIS pain measures and the Treatment Evaluation Inventory-Short Form (TEI-SF)...
September 19, 2023: Pediatric Blood & Cancer
https://read.qxmd.com/read/37718959/a-success-story-of-an-infantile-anaplastic-large-cell-lymphoma-a-case-report
#8
LETTER
Sowmya Jagadeeshwara, Nuthan Kumar Mulukere Kalappa, Prakruthi S Kaushik, Arun Kumar Ajjapanahalli Rajanna, Avinash Thumalapalli, Aruna Kumari Bandagadde Sreenivasa Bhat, Lingegowda Appaji
No abstract text is available yet for this article.
September 18, 2023: Pediatric Blood & Cancer
https://read.qxmd.com/read/37717146/pediatric-ttmv-rara-positive-relapsed-acute-promyelocytie-leukemia-responsive-to-venetoclax-and-achieving-long-remission-after-allogenic-transplantation
#9
LETTER
Jiaqi Chen, Xiaosu Zhou, Xue Chen, Qihui Chen, Junfang Yang, Yue Lu, Hongxing Liu
No abstract text is available yet for this article.
September 16, 2023: Pediatric Blood & Cancer
https://read.qxmd.com/read/37715727/an-srf-rearranged-malignant-cellular-myoid-neoplasm-with-a-novel-srf-mkl2-fusion
#10
LETTER
Cameron Crowell, Erica Schollenberg, Thai Hoa Tran, David Wilson, Michael Bezuhly, Daddy Mata-Mbemba, Cristina R Antonescu, Craig Erker
No abstract text is available yet for this article.
September 16, 2023: Pediatric Blood & Cancer
https://read.qxmd.com/read/37715725/use-of-larotrectinib-in-a-pediatric-patient-with-ntrk-rearranged-spindle-cell-neoplasm-and-subsequent-recurring-bone-fracture
#11
LETTER
Minji Kim, Kyung Taek Hong, Hyun Jin Park, Bo Kyung Kim, Yun Jeong Lee, Jung Yoon Choi, Young Hun Choi, Sung-Hye Park, Han-Soo Kim, Hyoung Jin Kang
No abstract text is available yet for this article.
September 16, 2023: Pediatric Blood & Cancer
https://read.qxmd.com/read/37715724/pd-l1-and-pd-1-expression-in-pediatric-post-transplant-burkitt-lymphoma-and-other-monomorphic-post-transplant-lymphoproliferative-disorders
#12
JOURNAL ARTICLE
Ashley V Geerlinks, Upton Allen, Bo-Yee Ngan, Angela Punnett
BACKGROUND: Post-transplant lymphoproliferative disorders (PTLD) develop as a consequence of immune suppression. Programmed death protein 1 (PD-1), a regulator of host immune activation, binds to programmed death-ligand 1 (PD-L1) to suppress the T-cell immune response. PD-1/PD-L1 pathway may play a role in PTLD. The objective was to describe intratumoral expression of PD-L1 and PD-1 in pediatric monomorphic PTLD, and assess if density of these cells is associated with progression-free survival (PFS) and overall survival (OS)...
September 16, 2023: Pediatric Blood & Cancer
https://read.qxmd.com/read/37715723/phase-1-study-of-cabozantinib-in-combination-with-topotecan-cyclophosphamide-for-patients-with-relapsed-ewing-sarcoma-or-osteosarcoma
#13
JOURNAL ARTICLE
Kevin Campbell, Andrew Posner, Nan Chen, Kerri Cavanaugh, Ketki Bhushan, Katherine A Janeway, David S Shulman, Suzanne George, Kelly Klega, Brian Crompton, Wendy B London, Steven G DuBois
PURPOSE: Phase 1 study assessing the safety and toxicity of cabozantinib in combination with topotecan and cyclophosphamide for relapsed osteosarcoma and Ewing sarcoma. METHODS: Oral cabozantinib (25 mg/m2 ) was administered daily for 21 (dose level 1) or 14 (dose level -1B) days. Topotecan (0.75 mg/m2 ) and cyclophosphamide (250 mg/m2 ) were administered intravenously (IV) on days 1-5. A modified 3+3 design based upon first cycle dose-limiting toxicities (DLT) was used for dose escalation...
September 16, 2023: Pediatric Blood & Cancer
https://read.qxmd.com/read/37715719/cost-effectiveness-analysis-of-dinutuximab-%C3%AE-for-the-treatment-of-high-risk-neuroblastoma-in-china
#14
JOURNAL ARTICLE
An-Le Shen, Jie Zhao, Li-Ting Yu, An-An Zhang, Bin Wu, Ye Fang, Ya-Li Han, Chen-Sui-Zi Li, Zhi-Ling Li, Yi-Jin Gao, Shun-Guo Zhang
BACKGROUND: Dinutuximab β can be used to treat children with high-risk neuroblastoma (NB). Due to its high price, whether dinutuximab β is cost-effective for the treatment of high-risk NB remains uncertain. Therefore, assessing the cost-effectiveness of dinutuximab β in children with high-risk NB is of high importance. METHODS: The health utilities and economic outcomes in children with high-risk NB were projected using a partitioned survival model...
September 16, 2023: Pediatric Blood & Cancer
https://read.qxmd.com/read/37712719/clinical-and-transcriptomic-characteristics-of-a-novel-smarcd2-mutation-that-disrupts-neutrophil-maturation-and-function
#15
JOURNAL ARTICLE
Laura Dotta, Giulia Baresi, Nicola Tamassia, Federica Calzetti, Francisco Bianchetto-Aguilera, Sara Gasperini, Elisa Gardiman, Marco Chiarini, Daniele Moratto, Giovanni Martellosio, Federico Serana, Moira Micheletti, Daniela Tregambe, Vincenzo Pintabona, Elena Soncini, Antonella Meini, Maria Federica Girelli, Alessandra Beghin, Arnalda Lanfranchi, Mattia Bugatti, Duilio Brugnoni, Annarosa Soresina, Alessandro Plebani, Marco Cassatella, William Vermi, Fulvio Porta, Raffaele Badolato
We report a novel case of SMARCD2 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily D, member 2) mutation successfully treated with hematopoietic stem cell transplantation. The female patient presented delayed cord separation, chronic diarrhea, skin abscesses, skeletal dysmorphisms, and neutropenia with specific granule deficiency. Analysis of the transcriptomic profile of peripheral blood sorted mature and immature SMARCD2 neutrophils showed defective maturation process that associated with altered expression of genes related to specific, azurophilic, and gelatinase granules, such as LTF, CRISP3, PTX3, and CHI3L1...
September 15, 2023: Pediatric Blood & Cancer
https://read.qxmd.com/read/37712671/-g-%C3%AE-a-%C3%AE-%C3%AE-%C3%AE-0-rm-g-gamma-rm-a-gamma-delta-beta-0-thalassemia-report-of-two-cases-in-a-family
#16
JOURNAL ARTICLE
Mana Tomiyama, Saki Takayama, Hiroko Konno, Takeshi Murakoshi, Masafumi Koga, Momoko Nakamura, Yasuhiro Yamashiro, Tadashi Matsubayashi
Case 1 presented with severe anemia and received an intrauterine blood cell transfusion at 33 weeks of gestation. The anemia spontaneously improved in early infancy. Case 2, the father of Case 1, had an uneventful birth with no evidence of anemia, though microcytic anemia was observed during childhood. The genetic analysis of the β-globin gene cluster identified a novel heterozygous deletion of DNA extending from the Gγ-globin gene downstream to the β-globin gene, confirming a diagnosis of (G γA γδβ)0 -thalassemia...
September 15, 2023: Pediatric Blood & Cancer
https://read.qxmd.com/read/37710331/consultation-patterns-before-and-after-embedding-pediatric-palliative-care-into-a-pediatric-hematology-oncology-clinic
#17
JOURNAL ARTICLE
Jacob R Greenmyer, Tiffany Ngo, Melissa Smith, Christopher Collura, Brenda Schiltz, Sarah R McCarthy
INTRODUCTION: Palliative care is a critical component of pediatric oncology care. Embedded pediatric palliative care (PPC) is relatively new in pediatric hematology/oncology (PHO) and may improve access, utilization, and quality of PPC. In June 2020, the Mayo Clinic PPC service transitioned from an afternoon, physically independent clinic to an all-day clinic embedded within PHO. METHODS: Retrospective chart review was used to quantify consultation rates from PHO to PPC in 12-month study periods before and after establishment of an embedded clinic...
September 14, 2023: Pediatric Blood & Cancer
https://read.qxmd.com/read/37710306/feasibility-of-pevonedistat-combined-with-azacitidine-fludarabine-cytarabine-in-pediatric-relapsed-refractory-aml-results-from-cog-advl1712
#18
JOURNAL ARTICLE
Katherine Tarlock, Xiaowei Liu, Charles G Minard, Emasenyie A Isikwei, Joel M Reid, Terzah M Horton, Elizabeth Fox, Brenda J Weigel, Todd Cooper
BACKGROUND: Outcomes for children with relapsed/refractory (R/R) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are poor, and new therapies are needed. Pevonedistat is an inhibitor of the NEDD-8 activating enzyme, a key regulator of the ubiquitin proteasome system that is responsible for protein turnover, with protein degradation regulating cell growth and survival. PROCEDURE: We evaluated the feasibility, toxicity, and pharmacokinetics (PK) of pevonedistat (20 mg/m2 days 1, 3, 5) in combination with azacitidine, fludarabine, cytarabine (aza-FLA) in children with R/R AML and MDS (NCT03813147)...
September 14, 2023: Pediatric Blood & Cancer
https://read.qxmd.com/read/37707323/visual-outcomes-after-bevacizumab-based-therapy-for-optic-pathway-glioma
#19
JOURNAL ARTICLE
Benjamin I Siegel, Daniel Nelson, Jason H Peragallo, Tobey J MacDonald, David S Wolf
In optic pathway glioma (OPG), bevacizumab-based therapy (BBT) has promising effects on radiographic tumor burden, but the impact on vision is less clear. This single-institution study characterized visual acuity (VA) and visual field (VF) outcomes in 17 pediatric OPG patients treated with BBT. VA was stable or improved in 14 patients. Nine patients had evaluable VF data, six of whom experienced stability or improvement. Among six patients with vision deterioration as a treatment indication, stable or improved was observed for both VA and VF in five patients...
September 14, 2023: Pediatric Blood & Cancer
https://read.qxmd.com/read/37705154/socioeconomic-status-significantly-impacts-childhood-cancer-survival-in-south-africa
#20
JOURNAL ARTICLE
Marc Hendricks, Annibale Cois, Jennifer Geel, Jaques van Heerden, Collet Dandara, Kharnita Mohamed, Kirsten A Donald, Mariana Kruger
BACKGROUND AND AIMS: Significantly discrepant survival rates have been documented in single disease childhood cancer cohorts in South Africa; those from higher socioeconomic groups were shown to have a significantly lower risk of death than those from less affluent households. This study aimed to determine the impact of socioeconomic status (SES) on childhood cancer survival using pooled South African data. METHODS: Five databases spanning January 2000 to December 2021 were interrogated...
September 13, 2023: Pediatric Blood & Cancer
journal
journal
20217
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.